Axsome Therapeutics (0HKF.L) Stock Price

$105 0%

Sign up
to add to portfolio

AI Score

Buy
  • Alternative

    10
  • Fundamental

    7
  • Technical

    5

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Axsome Therapeutics, AI stock picks, stock alerts and much more.

Sign up

0HKF.L AI Stock Analysis

AI stock analysis for 0HKF.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Axsome Therapeutics (0HKF.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Axsome Therapeutics (0HKF.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Axsome Therapeutics (0HKF.L), currently trading at $105, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About 0HKF.L

LSE
  • Axsome Therapeutics, Inc.

  • Symbol

    0HKF.L

  • Market

    LSE

  • Industry

    Medical - Pharmaceuticals

  • Market Cap

    5.1B

0HKF.L Alternative Data

Web Traffic

Axsome Therapeutics receives an estimated 45978 monthly visitors to axsome.com.

  • Web Traffic

    45978

  • Change from Previous Month

    41%

  • 3 Month Change

    31.9%

  • YoY Change

    31.9%

News Mentions

Axsome Therapeutics was mentioned 2 times in the news yesterday.

  • News Mentions

    2

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Twitter Followers

Axsome Therapeutics has 520 Twitter Followers on its main Twitter (also known as X) account, which is up by 13.8% over the last month.

  • Twitter Followers

    520

  • Daily Change

    0.2%

  • 1 Month Change

    13.8%

  • 3 Month Change

    18.2%

LinkedIn Followers

29,882 are following Axsome Therapeutics on LinkedIn, up by 3.1% over the last month.

  • LinkedIn Followers

    29882

  • Daily Change

    0.1%

  • 1 Month Change

    3.1%

  • 3 Month Change

    9.6%

Job Postings

Axsome Therapeutics has an estimated 82 open job postings, which is down -53.4% over the last month.

  • Job Postings

    82

  • Daily Change

    1.2%

  • 1 Month Change

    53.4%

  • 3 Month Change

    1.2%

Reddit Mentions

Axsome Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

LinkedIn Employees

According to LinkedIn, Axsome Therapeutics has 698 employees.

  • LinkedIn Employees

    698

  • Daily Change

    0.1%

  • 1 Month Change

    0%

  • 3 Month Change

    8.4%

Business Outlook

According to employee reviews, the business outlook among employees at Axsome Therapeutics is 79 out of 100 (bullish).

  • Business Outlook

    79

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

0HKF.L Financials

0HKF.L Key Metrics
  • Total Revenue

    $118.8M

  • Net Income

    -$74.9M

  • Earnings per Share

    -$1.56

  • Free cash flow

    -$26.2M

  • EBITDA

    -$70.5M

  • EBITDA Ratio

    -0.593975

  • Total Assets

    $568.5M

0HKF.L 2-year Revenue & Income
0HKF.L 2-year Free Cash Flow

0HKF.L Technicals

0HKF.L SMA
0HKF.L RSI

FAQ

What's the current price of Axsome Therapeutics (0HKF.L) Stock?
The price of an Axsome Therapeutics (0HKF.L) share is $105.

What's the market cap of Axsome Therapeutics?
The current market cap of Axsome Therapeutics is 5.1B.

Should I buy or sell 0HKF.L?
Multiple alternative data signals suggest that Axsome Therapeutics stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is Axsome Therapeutics a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Axsome Therapeutics stock. The bullish indicators suggest that Axsome Therapeutics' growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy Axsome Therapeutics (0HKF.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Axsome Therapeutics stock, given the bullish outlook.

What are some stocks similar to Axsome Therapeutics (0HKF.L) that investors often compare it to?
Axsome Therapeutics (0HKF.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.

What is the forecast for Axsome Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Axsome Therapeutics' stock price to be around $116.6 in 2026. Starting from the current price of $105, this represents a 11.1% change in price, indicating a bullish outlook for the stock.

How to buy Axsome Therapeutics (0HKF.L) Stock?
Axsome Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Axsome Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.